NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients

Phase 1

Active, not recruiting

Conditions: Acute Myeloid Leukemia

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration and Biopsy
Drug: Cytarabine
Drug: Decitabine and Cedazuridine
Drug: Daunorubicin
Drug: Venetoclax

First Posted Date: 2021-03-26

Last Posted Date: 2025-05-22

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 55

Registration Number: NCT04817241

Locations: 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

and more 4 locations

Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant

Phase 1

Recruiting

Conditions: Hairy Cell Leukemia
Hairy Cell Leukemia Variant

Interventions: Biological: CD22CART cell infusion

First Posted Date: 2021-03-25

Last Posted Date: 2025-04-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 27

Registration Number: NCT04815356

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Pilot Study to Investigate Magnetic Resonance (MR) Image Guided Focal Therapy in Prostate Cancer

Not Applicable

Recruiting

Conditions: Prostate Cancer

Interventions: Device: TULSA-PRO

First Posted Date: 2021-03-22

Last Posted Date: 2024-11-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 21

Registration Number: NCT04808427

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes

Phase 2

Active, not recruiting

Conditions: Acute Myeloid Leukemia
Acute Myeloid Leukemia With Multilineage Dysplasia
Myelodysplastic Syndrome
Acute Myeloid Leukemia Post Cytotoxic Therapy
Chronic Myelomonocytic Leukemia
Myeloproliferative Neoplasm

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration and Biopsy
Drug: Liposome-encapsulated Daunorubicin-Cytarabine
Drug: Pomalidomide

First Posted Date: 2021-03-17

Last Posted Date: 2025-05-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 50

Registration Number: NCT04802161

Locations: 🇺🇸
University of Cincinnati Cancer Center-West Chester, West Chester, Ohio, United States
🇺🇸
University of Kansas Hospital-Westwood Cancer Center, Westwood, Kansas, United States
🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States

and more 8 locations

Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers

Phase 1

Recruiting

Conditions: SCLC
Advanced Solid Tumor
High Grade Neuroendocrine Cancers
Small Cell Cancer

Interventions: Drug: Lurbinectedin
Drug: Berzosertib

First Posted Date: 2021-03-17

Last Posted Date: 2025-02-21

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 120

Registration Number: NCT04802174

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma

Phase 2

Suspended

Conditions: Ann Arbor Stage III Diffuse Large B-Cell Lymphoma
Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma
Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma
High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type
T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma Activated B-Cell Type
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements

Interventions: Procedure: Biospecimen Collection
Drug: Cyclophosphamide
Drug: Doxorubicin Hydrochloride
Drug: Oral Azacitidine
Drug: Prednisone
Other: Questionnaire Administration
Biological: Rituximab
Drug: Vincristine Sulfate

First Posted Date: 2021-03-16

Last Posted Date: 2025-04-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 422

Registration Number: NCT04799275

Locations: 🇺🇸
Banner University Medical Center - Tucson, Tucson, Arizona, United States
🇺🇸
University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States
🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

and more 173 locations

Developing Biomarkers of Dietary Intake: Dose Dependent Measurement of Sugar Intake

Phase 1

Recruiting

Conditions: Diet Therapy
Healthy Volunteers

Interventions: Behavioral: Diet with 20% of carb intake from soda
Behavioral: Diet with no soda
Behavioral: Diet with 50% of carb intake from soda

First Posted Date: 2021-03-16

Last Posted Date: 2025-05-20

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 60

Registration Number: NCT04799301

Locations: 🇺🇸
NIDDK, Phoenix, Phoenix, Arizona, United States

Incidence of Malignant Peripheral Nerve Sheath Tumor (MPNST) Development in Participants With Neurofibromatosis Type 1 (NF1) Receiving and Not Receiving Medical Therapies Directed at Plexiform Neurofibromas (PN)

Completed

Conditions: Neurofibromatosis 1
Peripheral Nerve Neoplasms, Malignant

First Posted Date: 2021-03-01

Last Posted Date: 2024-06-26

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 296

Registration Number: NCT04774289

Locations: 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States

Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis

Phase 2

Active, not recruiting

Conditions: Ulcerative Colitis
Colorectal Carcinoma

Interventions: Drug: Atorvastatin Calcium
Procedure: Biopsy of Colon
Procedure: Biospecimen Collection
Drug: Placebo Administration
Other: Questionnaire Administration

First Posted Date: 2021-02-24

Last Posted Date: 2025-04-29

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 42

Registration Number: NCT04767984

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸
University of Kansas Cancer Center, Kansas City, Kansas, United States

Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

Phase 3

Recruiting

Conditions: Primary Mediastinal Large B-Cell Lymphoma

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Procedure: Computed Tomography
Drug: Cyclophosphamide
Drug: Doxorubicin Hydrochloride
Procedure: Echocardiography Test
Drug: Etoposide Phosphate
Biological: Filgrastim
Procedure: Lumbar Puncture
Biological: Pegfilgrastim
Biological: Nivolumab
Procedure: Positron Emission Tomography
Radiation: Radiation Therapy
Drug: Prednisolone
Drug: Prednisone
Biological: Rituximab
Biological: Rituximab and Hyaluronidase Human
Drug: Vincristine Sulfate

First Posted Date: 2021-02-18

Last Posted Date: 2025-05-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 244

Registration Number: NCT04759586

Locations: 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
USA Health Strada Patient Care Center, Mobile, Alabama, United States
🇺🇸
Providence Alaska Medical Center, Anchorage, Alaska, United States

and more 231 locations

Home Terms & Conditions Privacy Policy